- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03613337
Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
Restenosis occurs for many different reasons. Over the years, many predictive clinical, biological, genetic, epigenetic, lesion-related, and procedural risk factors for restenosis have been identified.
Smoking is one of most important factors, however the results were contradictory. And the genetic factors of restenosis have been studied mostly in European populations. Based on literature review, study of candidate genes for restenosis in Chinese population was insufficient.
With due attention to this matter mentioned above, the investigators aim to preliminary explore genetic variation and smoking effect on clinical restenosis in patients diagnosed with after percutaneous coronary intervention in the Chinese population, with correlation analysis of factors and gene-set analysis of biological pathways related to restenosis and platelet approach were widely used in this study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The design of the study was retrospective study using secondary data from medical records of coronary heart disease patients who taking antiplatelet drugs and had genetic test at Peking University First Hospital. These patients were enrolled in a previous study, which was approved by the ethics committee of Peking University First Hospital (NO. 2013 [634]). The study investigated the association between genetic polymorphism and clopidogrel pharmacodynamics and drug adverse effect, and enrolled total 168 patients.
The primary endpoints clinical restenosis, defined as unplaned revascularization including arget vessel revascularization (TVR) or target lesion revascularization (TLR) , either by repeated percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). The platelet function was assessed using VerifyNow® P2Y12 (VN-P2Y12) assay (Accumetrics, San Diego, California, USA).
To analysis the association of SNP with unplaned revascularization and PRU, the investigators investigated pathways related to known platelet reaction (platelet production, platelet apoptosis, platelet activity, antiplatelet, platelet resistance, platelet adhesion, and etc.) and restenosis-related processes (inflammation, vascular function, proliferation and transcription) from the KEGG, BioCarta and Gene Cards .
The genetic statistical analyses were performed using the set-based test of PLINK v1.07 adjusted by smoking statues. During the set-based test of PLINK the joint effect of all genetic variation, fulfilling the test constraints, within the set of genes of pathway of interest is evaluated. First a single SNP analysis of all SNPs within the pathway set was performed, SNPs with the lowest p-value in the single SNP analysis were selected. This analysis was repeated 10,000 times in simulated datasets, subsequently, a mean SNP statistic was calculated from the single SNP statistics of a maximum amount of independent SNP with a p-value <0.01 SNPs are considered independent when the LD expressed in R2 is lower than 0.5. Analysis of gene mutation distribution conforms to the genetic equilibrium law of Hardy-Weinberg by chi-square test, P <0.05 is considered possible deviations of population distribution. The investigators use the result of 30 month as a replication, SNPs both significant in 18 month and 30 month were reported in the study.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Qian Xaing, Ph.D
- Phone Number: +86 010 66110802
- Email: xiangqz@126.com
Study Locations
-
-
-
Beijing, China, 100034
- Recruiting
- Peking University First Hospital
-
Contact:
- Qian Xiang, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Post percutaneous coronary intervention (PCI) patients;
- Patients received Dual antiplatelet therapy consisted of 100mg of aspirin daily and 75 mg of clopidogrel for at least 1 year after de novo percutaneous coronary intervention (PCI) ; If the end point occurred within 1 years, patients should use dual antiplatelet therapy during the period from the first to second percutaneous coronary intervention (PCI) .
Exclusion Criteria:
- Patients with cancer, viral hepatitis and other related diseases;
- The clinical data are incomplete.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
current smokers
Current smokers are those who continued smoking cigarettes more than 1 cigarette pre month after first percutaneous coronary intervention (PCI) .
|
The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
|
nonsmokers
Nonsmokers are those who never smoked in their lifetime.
|
The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
|
former smokers
Former smokers are those who had quit smoking after percutaneous coronary intervention (PCI) , and smoked less than 1 cigarette pre month after first percutaneous coronary intervention (PCI)
|
The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
clinical restenosis
Time Frame: follow up time from 1 to 5 years
|
Clinical restenosis, defined as unplaned revascularization including arget vessel revascularization (TVR) or target lesion revascularization (TLR) , either by repeated percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
The investigators will record the incidence of clinical restenosis events above through the medical record system, and compared the incidence through different smoking status.
|
follow up time from 1 to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Platelet reaction
Time Frame: Platelet function was detected after the clopidogrel efficiency reached homeostasis (clopidogrel 75mg daily for more than 7 days, or 300mg loading dose and 75mg daily for 5 days, or 600mg loading dose with 75mg for 3 days, and within 1 year after PCI
|
Platelet reaction (VerifyNow method) was detected after the clopidogrel efficiency reached homeostasis(clopidogrel 75mg daily for more than 7 days, or 300mg loading dose and 75mg daily for 5 days, or 600mg loading dose with 75mg for 3 days) , and the values will be compared by different smoking status.
|
Platelet function was detected after the clopidogrel efficiency reached homeostasis (clopidogrel 75mg daily for more than 7 days, or 300mg loading dose and 75mg daily for 5 days, or 600mg loading dose with 75mg for 3 days, and within 1 year after PCI
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCI71
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Heart Disease
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Shenyang Northern HospitalNot yet recruitingCoronary Heart Disease (CHD)China
-
Johns Hopkins UniversityCanon Medical Systems, USARecruiting
-
MedImmune LLCCompletedStable Coronary Heart DiseaseUnited States
-
Medical University of LodzBaxter Healthcare CorporationUnknownCHD - Coronary Heart DiseasePoland
-
University of ZurichCompletedStable Coronary Heart DiseaseSwitzerland
-
Hamad Medical CorporationMayo ClinicCompleted
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
Henan Institute of Cardiovascular EpidemiologyNot yet recruitingStable Coronary Heart Disease
Clinical Trials on clinical restenosis
-
Ospedale Santa Maria GorettiWithdrawnIn-stent Coronary Artery RestenosisItaly
-
Spanish Society of CardiologyAbbott Medical Devices; Fundación de Investigación Biomédica - Hospital Universitario... and other collaboratorsUnknownCoronary In-stnent RestenosisSpain
-
Centre Hospitalier Universitaire, AmiensWithdrawnRestenosis | Lower Limb ArteritisFrance
-
Silesian Centre for Heart DiseasesUnknownCoronary Artery Disease | Restenoses, Coronary | In-stent Restenosis | Contact Allergy | Metal Allergy
-
Sohag UniversityRecruitingAngiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery DiseasesEgypt
-
Shanghai MicroPort Medical (Group) Co., Ltd.Not yet recruitingCoronary Artery In-stent Restenosis
-
Pharmacosmos A/SLaboratory Corporation of America; BioStataWithdrawnRestless Legs Syndrome
-
Xuzhou Central HospitalUnknown
-
The Center for Rheumatic Disease, Allergy, & ImmunologyGrifols Therapeutics LLCCompletedInfections | IgG DeficiencyUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingCoronary Heart DiseaseChina